LASN500
Undisclosed
PreclinicalActive
Key Facts
About Lassen Therapeutics
Lassen Therapeutics is a clinical-stage biotechnology company developing antibody therapies targeting the IL-11 pathway for fibrotic diseases. Its lead asset, LASN01, is an anti-IL-11 receptor antibody currently in Phase 1 trials for Thyroid Eye Disease (TED), with plans to advance to Phase 2. The company is well-capitalized following an oversubscribed $85 million Series B financing in December 2023, which will also fund IND-enabling studies for a second program, LASN500. Lassen's strategy is centered on creating best-in-class biotherapeutics for conditions with high unmet medical need.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |